- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02322333
MLD10 in the Prevention of Migraine in Adults
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of MLD10 in the Prevention of Migraine Headache in Adults
Study Overview
Detailed Description
This is a multi-center, double-blind, randomized, placebo-controlled, parallel study of MLD10 for the prevention of migraine headache. The study population will consist of approximately 142 male and female subjects between 18 and 65 years of age with frequent episodic migraine as defined by International Classification of Headache Disorders-3beta criteria. Two MLD10 (243 mg (milligrams) of elemental magnesium) or placebo caplets will be taken twice daily for a total daily dose of 486 mg.
VISIT 1 - SCREENING
The following will be completed at Visit 1:
- Obtain written Informed Consent. The informed consent will be obtained in accordance with Good Clinical Practices (GCP) and all applicable regulatory requirements from each subject prior to participation in the study.
- Verify Inclusion/Exclusion Criteria. Subjects will meet all the inclusion and none of the exclusion criteria.
- Obtain demographics (race, ethnicity, sex, date of birth)
- Obtain medical, medication, and headache history. Data collected will include medical history and diagnoses, age at onset of migraine and other pertinent migraine/headache history, history of acute and prophylactic headache medications within the past 30 days, and history of other recent/concomitant medications.
- Obtain date of last menstrual cycle and perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Perform physical and neurological examinations.
- Measure vital signs (height, weight, resting heart rate, and blood pressure).
- Review Baseline Headache Diary. Subjects will be instructed to complete a daily online headache diary. Assessments to be captured are start/stop time, severity, associated symptoms, use of rescue medications, and unusual symptoms.
- Administer Columbia-Suicide Severity Rating Scale (C-SSRS).
- Schedule Visit 2.
VISIT 2 - RANDOMIZATION
- Verify Inclusion/Exclusion Criteria. Subjects must continue to meet all inclusion (including ≥ 3 days of migraine during baseline) and none of the exclusion criteria.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Record any changes to concomitant medications.
- Record any Serious Adverse Events (SAE) since signing the Informed Consent.
- Review Baseline Headache Diary for completeness and continuing eligibility.
- Randomize subject
- Review Month 1 Headache Diary instructions (same instructions as those discussed for Baseline Headache Diary).
- Dispense Month 1 study medication. Subjects will be instructed how to take study medication, prohibited medications/foods, dosage limitations of study medication, and storage requirements. Subjects will be instructed to return all used/partially used/unused study medication at next office visit and medications reconciliation will be performed to ensure a compliance of at least 80%. Subjects not complying at an 80% level will be withdrawn, unless otherwise approved by the Sponsor and/or Clinvest. (Estimated to be < 10%)
- Administer C-SSRS.
- Administer MIDAS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 3.
VISIT 3 - END OF TREATMENT PERIOD MONTH 1
- Record any changes to concomitant medications.
- Record any Non-Serious Adverse Events (NSAE) and/or SAEs.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Review Month 1 Headache Diary for completeness.
- Review instructions for Month 2 Headache Diary (same instructions as those discussed for Month 1 Headache Diary).
- Collect Month 1 unused study medication and used packaging. Confirm 85% compliance of medication usage per study protocol.
- Dispense Month 2 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit.
- Perform drug accountability.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 4.
VISIT 4 - END OF TREATMENT PERIOD MONTH 2
- Record any changes to concomitant medications.
- Record any NSAEs/SAEs.
- Perform urine pregnancy test, if appropriate. Results of the pregnancy test must be negative to continue in study.
- Measure vital signs (weight, resting heart rate, and blood pressure).
- Review Month 2 Headache Diary for completeness.
- Review instructions for Month 3 Headache Diary (same instructions as those discussed for Month 2 Headache Diary).
- Collect Month 2 unused study medication and used packaging. Confirm 85% compliance for medication usage per study protocol.
- Dispense Month 3 study medication and review the dosage limitations of study medication, storage requirements, and to return all used/partially used/unused study medication at next office visit.
- Perform drug accountability.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Schedule Visit 5.
VISIT 5 - END OF TREATMENT PERIOD MONTH 3
- Record any changes to concomitant medications.
- Record any NSAEs/SAEs.
- Perform urine pregnancy test, if appropriate.
- Measure vital signs (weight, resting heart rate, and blood pressure)
- Perform physical/neurological examinations.
- Collect Month 4 unused study medication and used packaging.
- Perform drug accountability.
- Administer SGIC & complete PGIC.
- Administer MIDAS.
- Administer C-SSRS.
- Collect serum samples for electrolytes, creatinine, and ionized Mg.
- Exit subject.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Carlsbad, California, United States, 92011
- The Research Center of Southern California
-
San Francisco, California, United States, 94109
- San Francisco Clinical Research Center
-
-
Florida
-
Oviedo, Florida, United States, 32765
- Physician Associates of Florida Research Department
-
-
Georgia
-
Snellville, Georgia, United States, 30039
- Dr. B. Abraham, P.C.
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49009
- Westside Family Medical Center, P.C.
-
-
Missouri
-
Saint Peters, Missouri, United States, 63303
- StudyMetrix Research
-
Springfield, Missouri, United States, 65807
- Clinvest Research, LLC
-
-
Tennessee
-
Memphis, Tennessee, United States, 38020
- Baptist Memorial Hospital
-
Nashville, Tennessee, United States, 37203
- Nashville Neuroscience Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female, in otherwise good health, 18 to 65 years of age.
- history of frequent episodic migraine (3-14 migraine days per month) (with or without aura) according to the International Classification of Headache Disorders-3beta for at least 3 months.
- onset of migraine before age 50.
- stable history of migraine at least 3 months prior to screening.
- not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
if female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as listed:
- complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for 7 days after completion or premature discontinuation from the study; surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); sterilization of male partner when in a monogamous relationship; intrauterine device with published data showing lowest expected failure rate is less than 1% per year; double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study.
- completion of online diary must be ≥ 80% compliance, unless otherwise approved by the Sponsor and/or Clinvest.
Exclusion Criteria:
- unable to understand the study requirements, the informed consent, or complete headache records as required per protocol.
- pregnant, actively trying to become pregnant, or breast-feeding.
- diagnosed with International Classification of Headache Disorders-3beta criteria for Chronic Migraine within 3 months prior to screening, at the time of screening, and/or during the baseline period.
- experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine within the last year.
- history of medication overuse headache (MOH) (Appendix II) in the 3 months prior to study enrollment or during the baseline phase.
- history of medication overuse (MO) of ergotamines, triptans, opioids, analgesics, NSAIDS and combination therapies, as defined by ICHD-3beta criteria and/or MO during baseline period.
- history of substance abuse and/or dependence, in the opinion of the Investigator.
- history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study.
- unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure.
- suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events.
has significant risk of suicide, defined as a "yes" answer to any of the following questions on the Columbia-Suicide Severity Rating Scale (C-SSRS), either at the screening visit (when assessing the prior 12 months) or at visit 2 (when assessing time since the screening visit):
- Questions 4 or 5 on the suicidal ideation section
- Any question on any item in the suicidal behavior section
- any psychiatric disorder with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in their ability to complete study activities.
- hypersensitivity, intolerance, or contraindication to the use of magnesium L-lactate dehydrate or any of its components.
- received any investigational agents within 30 days prior to Visit 1.
- plans to participate in another clinical study at any time during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MLD10
Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment.
A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window.
Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day.
Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
|
Other Names:
|
Placebo Comparator: Placebo
Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment.
A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window.
Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day.
Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Migraine Headache Days
Time Frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment period month 3 in subjects treated with MLD10 versus placebo. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3beta criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics [simple analgesics combined with opioids or barbiturate with or without caffeine]). |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache Days
Time Frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Comparison of the change from baseline of subjects treated with MLD10 versus placebo in the frequency of headache days during the 3 month treatment period. A headache day will be defined as any day not classified as a migraine day, but recorded headache of any severity and/or duration. |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Headache Duration
Time Frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the total cumulative minutes of headache during each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo. All headaches and/or migraines will be including in this outcome analysis. |
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Pain Severity
Time Frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the average pain severity at time of onset compared to each 28-day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo.
Headache pain severity was measured on a scale 1 = Mild, 2 = Moderate, 3 = Severe.
|
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Acute Medication Usage
Time Frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Change from baseline (28 day period) in the total number of acute headache pain medications used during each 28 day treatment period month 1, 2, & 3 in subjects treated with MLD10 versus placebo.
|
Day 1(Screening) - Day 116 (Visit 5 End of Study)
|
Migraine Disability Assessment Scale (MIDAS)
Time Frame: Day 29 (Randomization) & Day 116 (Visit 5 End of Study)
|
Change from Visit 2 to Visit 5 in the total MIDAS score in subjects treated with MLD10 versus placebo. The MIDAS test determines how severely migraines affect daily functioning. The responses of a variety of questions will be scored according to the questionnaire's scoring guide. A total score will be calculated ranging from 0-93. A score of 0-5 indicates little or no disability, 6-10 mild disability, 11-20, moderate disability, 21+ severe disability. |
Day 29 (Randomization) & Day 116 (Visit 5 End of Study)
|
Subject Global Impression of Change (SGIC)
Time Frame: Day 116 (Visit 5 End of Study)
|
Comparison of SGIC at Visit 5 in subjects treated with MLD10 versus placebo. Global impression of change rated by the subject will be assessed using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
Day 116 (Visit 5 End of Study)
|
Physician Global Impression of Change (PGIC)
Time Frame: Day 116 (Visit 5 End of Study)
|
Comparison of PGIC at Visit 5 in subjects treated with MLD10 versus placebo. The PGIC will be an impression of change rated by the investigator using a 7-point Likert scale ranging from -3 to 3 with -3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved. |
Day 116 (Visit 5 End of Study)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MLD10-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fundación de Investigación Biomédica - Hospital...Hospital Universitario La Fe; Hospital Vall d'Hebron; Hospital Universitario... and other collaboratorsRecruitingMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraSpain
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States